Possibility for tumor detection with fatty acid analogs

Area of Science:

• Nuclear medicine
• Radiochemistry
• Oncology

Background:

• Fatty acid tracers are crucial in nuclear medicine for metabolic imaging.
• Developing novel radiotracers for enhanced tumor visualization is an ongoing area of research.
• Assessing the efficacy of new radiotracers in preclinical models is essential before clinical application.

Purpose of the Study:

• To evaluate the potential of three novel fatty acid tracers for tumor imaging.
• To compare the tumor uptake and tumor-to-muscle ratios of these tracers in various preclinical tumor models.
• To determine the suitability of [18F]BMHDA, [18F]PA, and [125I]BMIPP for cancer detection.

Main Methods:

• Synthesis and radiolabeling of 17-[18F]fluoro-3-methylheptadecanoic acid ([18F]BMHDA), 16-[18F]fluoropalmitic acid ([18F]PA), and 15-(p-[125I]iodophenyl)-3-R,S-methylpentadecanoic acid ([125I]BMIPP).
• Administration of the radiotracers to rats and mice bearing 10 different tumor models.
• Quantification of tracer accumulation in tumors and muscle tissue.
• Calculation of tumor-to-muscle ratios and percentage injected dose per gram (%ID/g).

Main Results:

• [18F]BMHDA demonstrated the highest tumor/muscle ratios (2.3 in rat AH109A, 1.9 in mouse B16F1).
• Tumor accumulation for [18F]BMHDA was 0.41 ± 0.05% ID/g in AH109A and 4.29 ± 0.77% ID/g in B16F1.
• [125I]BMIPP and [18F]PA showed lower tumor/muscle ratios compared to [18F]BMHDA.

Conclusions:

• The evaluated novel fatty acid tracers, including [18F]BMHDA, exhibit limited potential for effective tumor imaging.
• The observed tumor-to-muscle ratios suggest that these tracers may not be optimal for differentiating tumors from surrounding healthy tissue.
• Further research into fatty acid analogs or alternative imaging strategies may be necessary for improved tumor detection.